The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Research into MPDL3280A for the Treatment of Lung Cancer

David Spigel, MD
Published Online: 8:57 PM, Wed June 4, 2014
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.

<<< Back to "Immunotherapy News from ASCO"
 



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.